Skip to Content

Diacomit Approval History

FDA Approved: Yes (First approved August 20, 2018)
Brand name: Diacomit
Generic name: stiripentol
Dosage form: Capsules and Powder for Oral Suspension
Company: Biocodex
Treatment for: Dravet Syndrome

Diacomit (stiripentol) is an anticonvulsant indicated for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam.

Development History and FDA Approval Process for Diacomit

DateArticle
Aug 21, 2018Approval FDA Approves Diacomit (stiripentol) for Seizures Associated with Dravet Syndrome

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide